XPhyto is a science-based cannabis company focused on formulation, clinical validation, and emerging European markets. XPhyto’s 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by the German Federal Institute for Drugs and Medical Devices (BfArM). XPhyto is pursuing additional opportunities in Germany including cultivation, processing, manufacturing, import, and distribution.
The bioscience company and its exclusive diagnostic partner, 3a-Diagnostics GmbH, are developing a point-of-care lateral flow test to detect COVID-19 viral RNA in patient saliva
Director Interviews
XPhyto Therapeutics subsidiary Vektor Pharma develops oral disintegrating film for European drug client
Director Interviews
XPhyto Therapeutics provides update on their oral film drug delivery platform with Vektor Pharma
